1 / 13

Drug Stores

Drug Stores. Trevor Yerrick Section 2. Agenda. Quick Background Drug Stores Industry Walgreen Co. Important Developments to Consider Alliance Boots Acquisition AmeriSource Bergen Agreement Full-Information Forecasting Sales EPM EATO Final Valuation Buy/Sell/Hold Recommendation.

maitland
Download Presentation

Drug Stores

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug Stores Trevor Yerrick Section 2

  2. Agenda • Quick Background • Drug Stores Industry • Walgreen Co. • Important Developments to Consider • Alliance Boots Acquisition • AmeriSource Bergen Agreement • Full-Information Forecasting • Sales • EPM • EATO • Final Valuation • Buy/Sell/Hold Recommendation

  3. Quick Background • Drug Store Industry • Traditional vs. In-store • Pharmacy Benefit Managers (PBMs) • “Nation’s largest drugstore chain” • 8,582 locations, including 8,116 drug stores • 2013: $72.2 B in sales, $45.5 B in prescription sales • Recent trend of expansion through acquisitions • Alliance Boots (45%) acquisition in 2012, option to purchase remaining 55% in 2015

  4. Best Sale Ever?

  5. Important Developments • Alliance Boots Acquisition (45% now, remaining 55% in 2016) • Synergies • 2014 - expected $375-425 million (increased after Q2) • 2016 - $1 billion • Revenues (AB + WAG) • 2016 - $130 billion • Operating Income • 2016 - $8.5-9.5 billion • Net Debt • 2016 - $11 billion

  6. Important Developments • AmeriSource Bergen Agreement • Leading pharmaceutical distributor • $79.7 in revenue (2012) • WAG + ASB • 10 year agreement worth $400 billion (to ASB) • Included 5% purchase of ASB stock by WAG (up to 23%) • Together - largest purchaser of pharmaceuticals worldwide • CVS expected to attempt a similar arrangement in future • Results • Better prices for branded and generic drugs • Significantly decreased inventory levels (daily delivery and complete distribution through ASB)

  7. Forecasting

  8. Full-Information Forecasting • Sales (See ‘Sales Forecast’ tab in spreadsheet) • Forecasted Prescription Sales and “Other” Sales to 2015 • Growth rates disrupted in 2012 & 2013 because of contract dispute with Express Scripts • 2016 – Adjusted for WAG management’s estimation of sales upon completion of Alliance Boots acquisition • $130 billion in sales by 2016 • 65-35 split – prescription sales vs. other in-store sales • Growth rate post-2016 - decreases by 0.5% per year until it reaches 3.5%

  9. Full-Information Forecasting • EPM (See ‘EPM Forecast’ tab in spreadsheet) • Synergies w/ Alliance Boots and AmeriSource Bergen • Cost of Sales – ASB • SG&A – AB and ASB • Operating income in 2016 – close to WAG management projection of $8.5-9.5 billion • As a result of synergies and rising sales, EPM steadily increases through 2022 • Approx. 5% post-2018

  10. Full-Information Forecasting • EATO (See ‘EATO Forecast’ tab in spreadsheet) • Synergies w/ AmeriSource Bergen • Inventories • Accounted for AB in Enterprise Assets and Liabilities using AB 2013 Annual Report • As a result of synergies and rising sales, EATO increases significantly post-2016 (acquisition of AB) • Approx. 6.50 in 2016 • 8.00 after 2020

  11. Final Valuation • Enterprise Value: • $80,906,113,490 • Adjusting for Mid-Year: • $85,055,377,700 • Adjusting for the Valuation Date: • $90,837,597,910 • See ‘Adjustments’ Tab

  12. Final Recommendation • Enterprise Value: • $90,837,597,910 • (NFL) • ($5,066,000,000) • Equity Value: • $85,771,597,910 • Number of Shares Outstanding: • 951,900,000 • Implied Share Value: • $90.11 • Current Share Price: • $67.38 • Recommendation: • BUY!!

  13. Questions?

More Related